Growth differentiation factor 15 alleviates diastolic dysfunction in mice with experimental diabetic cardiomyopathy

• DOI: 10.1016/j.celrep.2024.114573
• Publication Date: 2024-07-31T21:50:25Z
• Authors: Jordan S.F. Chan; Seyed Amirhossein...; Maria Areli Loren...; Keshav Gopal; Serena M. Pulente; Amanda A. Greenwell; Kunyan Yang; Christina T. Saed; Magnus J. Stenlund; Sally R. Ferrari; Indiresh A. Mangr...; Tanin Shafaati; Rakesh K. Bhat; Farah Eaton; Michael Overduin; Sebastian Beck Jø...; Gregory R. Steinberg; Erin E. Mulvihill; Gopinath Sutendra; John R. Ussher
• Keywords: Diabetic Cardiomyopathy

Growth differentiation factor 15 (GDF15) is a peptide with utility in obesity, as it decreases appetite and promotes weight loss. Because obesity increases the risk for type 2 diabetes (T2D) cardiovascular disease, imperative to understand actions of GDF15, especially since elevated GDF15 levels are an established biomarker heart failure. As loss should be encouraged early stages obesity-related prediabetes/T2D, where diabetic cardiomyopathy often present, we assessed whether treatment influences its pathology. We observed that alleviates diastolic dysfunction mice T2D independent This cardioprotection was associated reduction cardiac inflammation, which likely mediated via indirect actions, direct adult mouse cardiomyocytes differentiated THP-1 human macrophages failed alleviate lipopolysaccharide-induced inflammation. Therapeutic manipulation action may thus have both cardiomyopathy.